In the pivotal phase I TRANSCEND NHL 001 study, the CD19-directed CAR T-cell therapy lisocabtagene maraleucel demonstrated robust activity and manageable safety in relapsed/refractory LBCL.
Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.
Venetoclax plus ibrutinib combination regimen in high-risk untreated patients with CLL showed increasing MRD negativity with continued treatment up to 2 years.
Initial results from the phase II CAPTIVATE trial demonstrated that ibrutinib plus venetoclax yielded high rates of undetectable MRD in patients with previously untreated CLL/SLL.
LOXO-305, a non-covalent BTK inhibitor, demonstrated preliminary antitumor activity and manageable safety in pretreated B-cell malignancies including those resistant to previous BTKi therapy.
Lisocabtagene maraleucel showed manageable toxicity and clinical activity in heavily pretreated patients with high-risk CLL/SLL who failed prior ibrutinib.
CRs observed with single-agent mosunetuzumab, a bispecific antibody, in patients with R/R B-cell NHL, including patients with aggressive disease.
Patients with relapsed/refractory B-cell NHL who showed clinical response to liso-cel reported greater quality-of-life improvement vs nonresponders.
KTE-X19, a CD19-directed CAR T-cell therapy, produced high and durable response rates in relapsed/refractory mantle cell lymphoma.
Despite axi-cel being used in older patients and in more patients with high-risk disease, real-world efficacy and safety data for axi-cel in patients with large B-cell lymphoma was comparable to findings from the registrational ZUMA-1 trial.
Combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and safe as frontline therapy in CLL.